Plasma skin regeneration

Dallas -- A press release by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) reports that the Food and Drug Administration (FDA) has approved the Portrait PSR3 (Rhytec, Inc.), which uses plasma skin regeneration technology for the treatment of facial rhytides, superficial skin lesions, and actinic keratoses and full face and regional resurfacing.

The procedure, which is minimally invasive and adaptable for office use, uses nitrogen plasma that has a very low thermal time constant, meaning it gives up its thermal energy very rapidly, resulting in minimal skin damage. Additionally, because the plasma energy is not chromophore-specific, its energy flow to the skin architecture is predictable.

A full-face procedure requires about 30 minutes, results in minimal downtime and pain, and can be performed with topical lidocaine gel, with or without pre-treatment sedation.